US tariffs on Indian pharma will be hard to implement & inflationary: Systematix’s Vishal Manchanda

Vishal Manchanda, Pharma Analyst at Systematix Group, stated that Sun Pharmaceuticals stands to gain significantly from its recent acquisition of Checkpoint Therapeutics, as it provides access to the PD-L1 inhibitor, cosibelimab. This skin cancer treatment presents a substantial market opportunity.








